User login
Rare cancers, though individually rare by definition, impose a tremendous burden on adult and pediatric patient populations, especially when considering hematological cancers. In this Rare Diseases Report: Cancers, we bring you the latest information on new and ongoing developments in the treatment of some of these cancers through interviews with frontline researchers in the field.
- Survey reveals special impact of COVID-19 on patients with rare disorders
- New agents boost survival – and complexity – in chronic lymphocytic leukemia
- Targeted therapies may alter the landscape of MCL treatment
- Will CAR T push beyond lymphoma? There’s no guarantee
Rare cancers, though individually rare by definition, impose a tremendous burden on adult and pediatric patient populations, especially when considering hematological cancers. In this Rare Diseases Report: Cancers, we bring you the latest information on new and ongoing developments in the treatment of some of these cancers through interviews with frontline researchers in the field.
- Survey reveals special impact of COVID-19 on patients with rare disorders
- New agents boost survival – and complexity – in chronic lymphocytic leukemia
- Targeted therapies may alter the landscape of MCL treatment
- Will CAR T push beyond lymphoma? There’s no guarantee
Rare cancers, though individually rare by definition, impose a tremendous burden on adult and pediatric patient populations, especially when considering hematological cancers. In this Rare Diseases Report: Cancers, we bring you the latest information on new and ongoing developments in the treatment of some of these cancers through interviews with frontline researchers in the field.
- Survey reveals special impact of COVID-19 on patients with rare disorders
- New agents boost survival – and complexity – in chronic lymphocytic leukemia
- Targeted therapies may alter the landscape of MCL treatment
- Will CAR T push beyond lymphoma? There’s no guarantee
